LAVAL – Moderna has completed construction of its state-of-the art mRNA manufacturing facility in Laval, Quebec. The facility is expected to be ready to manufacture respiratory mRNA vaccines for Canadians in 2025, pending regulatory approvals and certifications, ensuring all vaccines manufactured meet the strictest quality, safety and performance standards.
The construction of this facility marks an important milestone in Moderna’s strategic partnership with the federal government to support domestic preparedness for future pandemics for all Canadians. This initiative will also generate and support high-skilled employment opportunities. The building of the facility was made possible in part by funding from the Government of Quebec through Investissement Québec.
This manufacturing site reflects Moderna’s commitment to environmental sustainability. It is designed to eliminate most fossil fuel usage, and benefits from Quebec’s electricity generated is from renewable resources, supporting Moderna’s drive to achieve net-zero emissions by 2030 in scopes 1 and 2.
Moderna currently has 45 therapeutic and vaccine programs in its pipeline across infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, including nine in late-stage development.
“With infectious diseases continuing to pose a significant health challenge, our mRNA platform can play a pivotal role against current and future threats. Canada’s role in global health is critical, and with this facility, Moderna is honoured to contribute to its robust scientific community and public health leadership in driving innovation and transformative medicine forward.” Stéphane Bancel, CEO Moderna